A targeted drug with focused radiation for HER2-positive breast cancer that spread to the brain
Original title: Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, so the answers are not in yet.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a targeted drug plus focused radiation for brain spots from breast cancer.
Who this trial is for. This trial is for people with HER2-positive breast cancer that has spread, who have just been found to have spots in the brain. They get a drug called trastuzumab deruxtecan, also called T-DXd, given through a vein every 3 weeks. They also get focused radiation aimed at the brain spots. It is meant for people with a small number of brain spots.
Where it stands. This trial has not reported results. People stay on the drug until the cancer grows, side effects get too hard, or they choose to stop. The team plans a check of how things are going after the first 30 people. Up to 60 people may take part. No answers are in yet.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you could ask your care team about it. They know your case and can say whether it is worth looking into. They can also explain other choices you have right now.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not proven care. Joining one is not a promise that it will help you. It is not a cure, and no one can say yet what it will do.
Source: ClinicalTrials.gov, October 29, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.